Aurobindo Pharma Limited specializes in the development and manufacturing of antiretroviral drugs. The company's main focus is on providing treatment options to over 125 countries and contributing to UNAIDS' goal of achieving 95-95-95 by 2030. Aurobindo Pharma is committed to pediatric HIV treatment and has an R&D infrastructure for developing generic versions of the latest treatment options.
Basic Information
Key Executives
Purchase this report to view the information.
Non Executive Chairman
Purchase this report to view the information.
Vice Chairman & Whole Time Director
Purchase this report to view the information.
Independent and Non Executive Director
Purchase this report to view the information.
Independent and Non Executive Director
Purchase this report to view the information.
Independent and Non Executive Director
Ownership Details
Purchase this report to view the information.
33.5%
Purchase this report to view the information.
29.01%
Purchase this report to view the information.
4.37%
Purchase this report to view the information.
4.3%
Purchase this report to view the information.
3.45%
Subsidiaries
1980 Puren Pharma GmbH (Germany)
100%
APL Swift Services (Malta) Ltd. (Malta)
100%
Company Performance
Financial values in the chart are available after Aurobindo Pharma Ltd. report is purchased.
Looking for more than just a company report?
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency INR. Absolute financial data is included in the purchased report.
Total operating revenue
6.25%▲
Operating Profit/Loss (EBIT)
5.51%▲
Net Profit/Loss for the Period
-0.08%▼
Operating Profit Margin (ROS)
-0.16%▼
Return on Equity (ROE)
-3.54%▼
